15.09.2011Neanderthal/modern human: an uncommon common descentYou are hereNewsNeanderthal/modern human: an uncommon common descent
Prof. Laurent Excoffier, from the SIB Swiss Institute of Bioinformatics and the University of Bern, and Dr. Mathias Currat from the University of Geneva, established a computer model to understand why our Neanderthal ancestry is so low. They simulated DNA samples of modern French and Chinese people to assess the interbreeding success rate under different Paleolithic demographic scenarios. Their study reveals that the interbreeding success rate is less than 2%, due to strong barriers to gene flow between the two species. The results of their study “Strong reproductive isolation between humans and Neanderthals inferred from observed patterns of introgression" are published this week in the prestigious journal PNAS.
BioAlps World Visibitlity Package 201918.03.2019A yearly international programme for our affiliated companies to increase their visibility.
BioAlps World Visibitlity Package 2019A yearly international programme for our affiliated companies to increase their visibility.
Eclosion2 & cie SCPCInvestor, Public / Bank / Venture Capital FundsEclosion2 & cie SCPC is a life science investment fund focusing on translating cutting edge science into biotechnology companies developing transformational best-in-diseases therapeutics and platform technologies.
We are builders. Eclosion's approach is defined by its unique entrepreneurial mindset leading to a strong operational and investment commitment to start-up enterprises. Eclosion is driven by an experienced management team which brings together scientific, operational and financial expertise and a successful track record of company creation, value generation and development of new therapeutics that will transform human healthcare.
We focus on highly innovative science and early stage companies developing new approaches to address high unmet medical needs. Eclosion2 fund’s portfolio companies have developed first-in-class drugs with high potential value to patients in fields such as multiple sclerosis, fibrosis or oncology.
We are enablers. Eclosion private investment fund supports portfolio companies from seed to capital stage up to clinical proof of concept, making significant long term operational and financial commitments to companies that have the potential to change the way patients are treated.